Tumor Necrosis Factor alpha, Recombinant, Porcine (TNFa)

TNF is secreted by macrophages, monocytes, neutrophils, T-cells, NK-cells following their stimulation by bacterial LPS . Cells expressing CD4 secrete TNF-alpha while CD8 cells secrete little or no TNF-alpha. The synthesis of TNF-alpha is induced by many different stimuli including interferons, IL2 , GM-CSF.\n\nDescription: \nRecombinant Porcine TNF-a produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 157 amino acids and having a molecular mass of 17,274 Dalton. Porcine TNF-alpha is purified by standard chromatographic techniques.\n\nAmino Acid Sequence: \nThe sequence of the first five N-terminal amino acids was determined and was found to be Met-Leu-Arg-Ser-Ser.\n\nDimers and Aggregates: \nLess than 1% as determined by silver-stained SDS-PAGE gel analysis.\n\nBiological Activity: \nPorcine TNF-alpha is fully biologically active when compared to standard. The ED50 as determined by the cytotoxicity of porcine PK15 cells was found to be < 0.008ng/ml.\n\nEndotoxin: \n(same/less than) 0.1ng/ug (IEU/ug) of Porcine TNF-alpha.\n\nProtein Content: \nProtein quantitation was carried out by two independent methods:\n1. UV spectroscopy at 280 nm using the absorbency value of 1.26 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics).\n2. Analysis by RP-HPLC, using a calibrated solution of TNF-alpa as a Reference Standard.\n\nSolubility: \nIt is recommended to reconstitute the lyophilized Porcine TNF-alpha in sterile 18M-cm H2O not less than 100microg/ml, which can then be further diluted to other aqueous solutions.\n\nStability: \nLyophilized Porcine TNF-a although stable at room temperature for 3 weeks, should be stored desiccated below -180C. Upon reconstitution TNF-alpha should be stored at 40C between 2-7 days and for future use below -180C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

T9160-15P1

Size

5ug

Form

Supplied as a lyophilized powder without additives.

Purity

(same/more than) 95% as determined by RP-HPLC, anion-exchange FPLC and/or reducing and non-reducing SDS-PAGE Silver Stained gel.

References

1. Who might be predisposed to the development of serious side effects when treated with TNF-alpha antagonist?\n\nClin Exp Rheumatol 2006 Mar-Apr;24(2):211; author reply 211\n\n2. The effect of periodontal therapy on TNF-alpha, IL-6 and metabolic control in type 2 diabetics.\n\nJ Dent Hyg 2006 Spring;80(2):7\n\n3. Cell to cell contact through ICAM-1-LFA-1 and TNF-alpha synergistically contributes to GM-CSF and subsequent cytokine synthesis in DBA/2 mice induced by 1,3-beta-D-Glucan SCG.\n\nJ Interferon Cytokine Res 2006 Apr;26(4):235-47\n\n4. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease.\n\nJ Immunol 2006 May 15;176(10):6294-301\n\n5. Interleukin-17 acts independently of TNF-alpha under arthritic conditions.\n\nJ Immunol 2006 May 15;176(10):6262-9\n\n6. Peptide YY attenuates STAT1 and STAT3 activation induced by TNF-alpha in acinar cell line AR42J.\n\nJ Am Coll Surg 2006 May;202(5):788-96